Focused On-demand Library for ATP-dependent RNA helicase DHX29

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

DEAH box protein 29; Nucleic acid helicase DDXx

Alternative UPACC:

Q7Z478; O75549; Q63HN0; Q63HN3; Q8IWW2; Q8N3A1; Q9UMH2


ATP-dependent RNA helicase DHX29, also known as DEAH box protein 29 and Nucleic acid helicase DDXx, plays a crucial role in translation initiation. It is part of the 43S pre-initiation complex, enhancing initiation on mRNAs with structured 5'-UTRs by promoting NTPase-dependent 48S complex formation. DHX29 binds specifically to the 40S ribosome near the mRNA entrance, facilitating efficient translation initiation in higher eukaryotes.

Therapeutic significance:

Understanding the role of ATP-dependent RNA helicase DHX29 could open doors to potential therapeutic strategies. Its pivotal function in translation initiation makes it a compelling target for drug discovery, aiming to modulate protein synthesis in diseases where this process is dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.